Kalaris Therapeutics, Inc. Common Stock KLRS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$44.1M+41.9% | -$43.44M+37.2% | -$55.47M+48.1% | -$81.66M+27.8% | -$75.96M+50.2% | ||
| —— | —— | —— | —— | —— | ||
| $2.14M+73.0% | $1.94M+116% | $1.88M-82.3% | $1.51M-92.8% | $1.24M-96.0% | ||
| -$42.51M-80.2% | -$38.37M-85.6% | -$39.16M+10.1% | -$32.16M+56.4% | -$23.59M+75.6% | ||
| -$65.14M-230% | -$19.72M-121% | -$9.79M-108% | $15.14M— | $50.07M— | ||
| —— | —— | —— | —— | $119.83M— | ||
| —— | —— | —— | —— | $96.24M+509% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kalaris Therapeutics, Inc. Common Stock generate?
- Kalaris Therapeutics, Inc. Common Stock (KLRS) generated -$42.5M in operating cash flow over the trailing twelve months.
- What is Kalaris Therapeutics, Inc. Common Stock's free cash flow?
- After $36.5K of capital expenditures, Kalaris Therapeutics, Inc. Common Stock's free cash flow was -$86.8M over the trailing twelve months.
- Where does Kalaris Therapeutics, Inc. Common Stock's cash flow data come from?
- Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.